SMMTSummit Therapeutics Inc.

SMMT Stock Price, Valuation & Chart | Summit Therapeutics Inc.

Compare

$12.730-0.43 (-3.27%)

At close · 24 Aug 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology SMMT intrinsic value Is SMMT overvalued or undervalued

Overview Financials Dividends Ratios

SMMT Historical price chart

SMMT Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization10.16B

PE Ratio-11.37

EPS-1.12

Trading Volume7.02M

Today's High/Low13.21/12.22

Dividend Yield0.00

52 Week High/Low30.05/12.07

Shares Outstanding797.75M

SMMT Financial Statement

SMMT Analyst ratings

SMMT Analysis & performance metrics

SMMT Company profile

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America.…

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III…

SMMT Management team

Name

Position

Mahkam Zanganeh D.D.S., M.B.A.CEO

Co-Chief Executive Officer, President & Director

Manmeet Singh Soni CPACFO

Chief Operating Officer, Chief Financial Officer & Director

Fong Clow

Chief Biometrics Officer

Shelley D. Spray

Chief Education & Brand Officer

Urte Gayko Ph.D.

Chief Regulatory, Quality & Pharmacovigilance Officer

Laura Q. M. Chow M.D.

Senior Vice President of Clinical Development

Robert W. DugganCEO

Co-Chief Executive Officer & Executive Chairman

Dame Kay Davies DBE, FRS CBE

Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor

Name

Position

Mahkam Zanganeh D.D.S., M.B.A.CEO

Co-Chief Executive Officer, President & Director

Manmeet Singh Soni CPACFO

Chief Operating Officer, Chief Financial Officer & Director

Fong Clow

Chief Biometrics Officer

Shelley D. Spray

Chief Education & Brand Officer

Urte Gayko Ph.D.

Chief Regulatory, Quality & Pharmacovigilance Officer

Laura Q. M. Chow M.D.

Senior Vice President of Clinical Development

Robert W. DugganCEO

Co-Chief Executive Officer & Executive Chairman

Dame Kay Davies DBE, FRS CBE

Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor

Management Team

Mahkam Zanganeh D.D.S., M.B.A.CEO

Co-Chief Executive Officer, President & Director

Manmeet Singh Soni CPACFO

Chief Operating Officer, Chief Financial Officer & Director

Fong Clow

Chief Biometrics Officer

Shelley D. Spray

Chief Education & Brand Officer

Urte Gayko Ph.D.

Chief Regulatory, Quality & Pharmacovigilance Officer

Laura Q. M. Chow M.D.

Senior Vice President of Clinical Development

Robert W. DugganCEO

Co-Chief Executive Officer & Executive Chairman

Dame Kay Davies DBE, FRS CBE

Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor

Management

Mahkam Zanganeh D.D.S., M.B.A.CEO

Co-Chief Executive Officer, President & Director

Manmeet Singh Soni CPACFO

Chief Operating Officer, Chief Financial Officer & Director

Fong Clow

Chief Biometrics Officer

Shelley D. Spray

Chief Education & Brand Officer

Urte Gayko Ph.D.

Chief Regulatory, Quality & Pharmacovigilance Officer

Laura Q. M. Chow M.D.

Senior Vice President of Clinical Development

Robert W. DugganCEO

Co-Chief Executive Officer & Executive Chairman

Dame Kay Davies DBE, FRS CBE

Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor

Total 8 executives

SMMT Frequently asked questions

What is Summit Therapeutics Inc. (SMMT) Stock Price?

Current stock price of Summit Therapeutics Inc. (SMMT) stock is $12.730. The stock price is -3.27% lower in the session. The intraday range can be seen from this page. Volume of Summit Therapeutics Inc. (SMMT) stock is 7.02M.

Last updated at 24 Aug 2026, 08:00 pm.

Why is the Summit Therapeutics Inc. (SMMT) stock price going up or down today?

The stock price of Summit Therapeutics Inc. (SMMT) can change with earnings, company news, and overall market sentiment. Summit Therapeutics Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Summit Therapeutics Inc. stock expensive at its current price?

Whether Summit Therapeutics Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for SMMT on this page is -11.37. EPS on this page is -1.12. Compare those figures with peers and growth expectations before deciding if the current Summit Therapeutics Inc. price is justified.

How has the stock price of Summit Therapeutics Inc. (SMMT) performed historically?

Historical performance for Summit Therapeutics Inc. (SMMT) is shown on the price chart on this page. Review multi-period moves alongside volume to see how SMMT reacted to past earnings and market events.

Should I buy Summit Therapeutics Inc. (SMMT) stock, at this price?

Buying Summit Therapeutics Inc. (SMMT) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.